Results from the phase 3 placebo-controlled MAPP2 trial show that MDMA-assisted therapy reduces post-traumatic stress disorder (PTSD) symptoms and functional impairment in a diverse population with moderate to severe PTSD.
- Jennifer M. Mitchell
- Marcela Ot’alora G.
- Amy Emerson